Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
Pablo D. García, Matthew T. Burger(Novartis (Switzerland)), Jamie Narberes(Novartis (Switzerland)), Tatiana Zavorotinskaya(Novartis (Switzerland)), Joseph Castillo(Novartis (Switzerland)), Christine Fritsch, Stephen E. Basham(Therapeutics Clinical Research), Mika Lindvall, Marjorie Ison(Novartis (Switzerland)), J. Alex Aycinena, Jing Lü(Center for Drug Evaluation and Research), Yingyun Wang(Revolution Medicines (United States)), Michael L. Doyle(Novartis (Switzerland)), Paul Feucht(Novartis (United States)), Robert Warne(Novartis (Switzerland)), Christopher J. Wilson, Xiaohong Niu(Nanjing Traditional Chinese Medicine Hospital), J. G. Chan(Novartis (Switzerland)), Joerg Trappe(Novartis (Switzerland)), Peter Drueckes(Novartis (Switzerland)), Estelle Pfister(Novartis (Switzerland)), Jocelyn Holash(Regeneron (United States)), Wooseok Han, Cornelia Bellamacina, Tiffany Tsang(Novartis (United States)), Christie Fanton(Nektar Therapeutics (United States)), Min Chen(Novartis (Switzerland)), Jiong Lan(Novartis (Switzerland)), Yumin Dai(Robert Bosch (Germany)), Jianjun Yu(University of Michigan), John L. Langowski(Novartis (Switzerland)), Richard Zang(Genesys (United States)), Audrey Kauffmann(Novartis (Switzerland)), Gisele Nishiguchi(St. Jude Children's Research Hospital)
Cited by 111
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k